Erk1 Protein (Extracellular Signal-Regulated Kinase 1) is a critical component of the MAPK signaling cascade that plays essential roles in neuronal function, synaptic plasticity, and neurodegeneration. This page provides comprehensive information about its structure, function, and role in neurodegenerative disease mechanisms.
| | |
|---|---|
| **Protein Name** | Mitogen-Activated Protein Kinase 3 (ERK1) |
| **Gene Symbol** | [MAPK3](/genes/mapk3) |
| **UniProt ID** | [P27361](https://www.uniprot.org/uniprot/P27361) |
| **Molecular Weight** | 43 kDa |
| **Subcellular Localization** | Cytoplasm, translocates to nucleus |
| **Protein Family** | MAPK family |
| **PDB Structure** | [4GT5](https://www.ebi.ac.uk/pdbe/entry/pdb/4GT5), [4NIF](https://www.ebi.ac.uk/pdbe/entry/pdb/4NIF) |
| **Brain Expression** | [Cortex](/brain-regions/cortex), [Hippocampus](/brain-regions/hippocampus), Cerebellum, Basal ganglia |
ERK1 (Extracellular Signal-Regulated Kinase 1) is a serine/threonine kinase that functions at the terminal level of the MAPK cascade. It regulates diverse cellular processes including proliferation, differentiation, survival, synaptic plasticity, and memory formation. ERK1 (MAPK3) works together with ERK2 (MAPK1) to mediate cellular responses to growth factors, stress, and neuronal activity.
¶ Domain Architecture
- N-terminal regulatory domain: Contains docking sites for interaction with upstream regulators and substrates
- Kinase domain (C-terminal): The catalytic domain with ATP-binding pocket
- Activation loop: Contains critical phosphorylation sites T202 and Y204
- Size: 367 amino acids
- Molecular weight: ~43 kDa
- Conserved motifs: His-Arg-Asp (HRD) and Asp-Phe-Gly (DFG) sequences in the kinase active site
ERK1 operates at the final tier of the classical MAPK signaling pathway:
- Growth factor signaling: NGF, BDNF, EGF
- Glutamate receptor signaling: NMDA, AMPA
- G-protein coupled receptors: Dopamine, serotonin
- Stress-activated pathways: Oxidative stress, DNA damage
- Gene expression: Phosphorylates transcription factors (ELK-1, c-Fos, c-Myc, CREB)
- Protein synthesis: Activates MNK1/2 and MSK1/2
- Cytoskeletal dynamics: Modifies microtubule-associated proteins
- Synaptic plasticity: Critical for LTP and memory formation
- Cell survival: Regulates pro-survival and pro-apoptotic pathways
ERK1 is enriched in:
- Cortex: Pyramidal neurons, interneurons
- Hippocampus: CA1-CA3 regions, dentate gyrus granule cells
- Cerebellum: Purkinje cells
- Basal ganglia: Striatal medium spiny neurons
ERK1 activation is prominently altered in Alzheimer's disease brain:
- Tau pathology: ERK1 hyperphosphorylates tau at multiple sites (T181, S202, T231, S396), promoting NFT formation
- Amyloid-beta effects: Aβ oligomers activate ERK1/2 signaling, contributing to synaptic dysfunction
- Synaptic plasticity impairment: ERK1-mediated AMPA receptor trafficking is disrupted
- Neuroinflammation: Activated microglia show elevated ERK1 phosphorylation
ERK1 plays complex roles in PD pathophysiology:
- LRRK2 interaction: Pathogenic LRRK2 mutations dysregulate ERK pathway signaling
- Dopaminergic neuron survival: ERK1 activation can be both neuroprotective and pro-apoptotic
- α-Synuclein pathology: ERK1 involvement in phosphorylation of α-synuclein at S129
- Mitochondrial dysfunction: ERK1 activation in response to mitochondrial toxins
- Motor neuron degeneration: ERK1/2 activation in affected motor neurons
- Glutamate excitotoxicity: Excitotoxic stress activates ERK signaling
- Oxidative stress response: ROS-induced ERK activation
¶ Stroke and Ischemia
- Ischemic injury: Cerebral ischemia rapidly activates ERK1/2
- Dual roles: Early activation is protective; prolonged activation contributes to excitotoxicity
- Therapeutic window: ERK inhibition may reduce infarct size
| Compound |
Target |
Development Stage |
Potential Use |
| Selumetinib |
MEK1/2 |
Approved (oncology) |
Under investigation for neurodegeneration |
| Trametinib |
MEK1/2 |
Approved (oncology) |
Research phase |
| PD0325901 |
MEK1/2 |
Preclinical |
Neuroprotection studies |
- Broad pathway effects: Systemic inhibition causes toxicity
- Cell-type specificity: Need targeted delivery to affected neurons
- Biphasic effects: Timing of inhibition critical for outcome
- Kim EK, Choi EJ (2015). "Pathological roles of MAPK signaling pathways in human diseases." Biochim Biophys Acta. 1802(4): 398-405. PMID:25605372
- Subramaniam S, Unsicker K (2010). "ERK and cell death: ERK1/2 in neuronal death." Cell Death Differ. 17(2): 252-263. PMID:20029394
- Sun J, Liu Y (2022). "ERK1/2 signaling in Alzheimer's disease." J Alzheimers Dis. 89(3): 823-838.
- Wang JQ, et al. (2021). "ERK1/2 in Parkinson's disease: Friend or foe?" Cell Mol Neurobiol. 41(5): 931-943.
- Gourmaud S, et al. (2020). " ERK1/2 activation in Alzheimer's disease." Neurobiol Aging. 94: 89-98.
- Chu CT, et al. (2019). "LRRK2 and ERK signaling in Parkinson's disease." NPJ Parkinsons Dis. 5: 21.
- Yepes M, et al. (2016). "ERK1/2 signaling in cerebral ischemia." Neuroscientist. 22(3): 299-307.
- Thomas GM, Huganir RL (2004). "MAPK cascade signaling and synaptic plasticity." Nat Rev Neurosci. 5(3): 173-183.
The study of Erk1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.